Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial (Q35321191)

7 August 2017

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial (English)

1 reference

7 August 2017

0 references

0 references

3

Johnny Ludvigsson

1 reference

7 August 2017

Robert J Ferry

6

0 references

Ronald L. Wilder

12

object named as

Ronald L Wilder

1 reference

ORCID Public Data File 2021

7 August 2017

1 reference

Kevan C Herold

18

object named as

Kevan C Herold

1 reference

7 August 2017

Nicole Sherry

1

1 reference

7 August 2017

William Hagopian

2

1 reference

7 August 2017

Sunil M Jain

4

1 reference

7 August 2017

Jack Wahlen

5

1 reference

7 August 2017

Bruce Bode

7

1 reference

7 August 2017

Stephen Aronoff

8

1 reference

7 August 2017

Christopher Holland

9

1 reference

7 August 2017

David Carlin

10

1 reference

7 August 2017

Karen L King

11

1 reference

7 August 2017

Stanley Pillemer

13

1 reference

7 August 2017

Ezio Bonvini

14

1 reference

7 August 2017

Syd Johnson

15

1 reference

7 August 2017

Kathryn E Stein

16

1 reference

7 August 2017

Scott Koenig

17

1 reference

7 August 2017

Anastasia G Daifotis

19

1 reference

7 August 2017

Protégé Trial Investigators

20

1 reference

7 August 2017

language of work or name

English

0 references

publication date

28 June 2011

1 reference

7 August 2017

1 reference

7 August 2017

378

1 reference

7 August 2017

487-497

1 reference

7 August 2017

9790

1 reference

Type 1 diabetes: etiology, immunology, and therapeutic strategies

7 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Immunotherapy of type 1 diabetes: where are we and where should we be going?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

GAD treatment and insulin secretion in recent-onset type 1 diabetes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of randomized trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Insulin secretion in type 1 diabetes

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Effects of insulin in relatives of patients with type 1 diabetes mellitus

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

In vitro characterization of five humanized OKT3 effector function variant antibodies.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191495

Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960931-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960931-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Diagnosis and classification of diabetes mellitus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21719095

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/S0140-6736(11)60931-8

1 reference

7 August 2017

1 reference

7 August 2017

1 reference